The largest analysis to examine the best way to lower levels of ‘bad’ cholesterol in patients with blocked arteries shows that they should immediately be given a combination of a statin and another drug called ezetimibe, rather than statins alone. This could prevent thousands of deaths a year from heart attacks, strokes and other cardiovascular diseases. The meta-analysis of 108,353 patients in 14 studies who were at very high risk of suffering heart attack or stroke, or who had already suffered one of these cardiovascular events is published in the journal Mayo Clinic Proceeding.

Israel’s national earthquake warning system, “Truaa,” which became operational in 2022, has positioned the country alongside other advanced nations that utilize early warning systems for earthquakes. However, one of the main challenges in such systems is balancing speed and accuracy: a quick warning may save lives, but if it is based on limited data, it may be wrong and result in false alarms and unnecessary injuries. A new study conducted by Dr. Yonat Zwebner, a consumer behavior expert at the Arison School of Business at Reichman University, in collaboration with Dr. Ran Nof and Dr. Gony Biran from the Geological Survey of Israel, examined this trade-off between urgency and accuracy. The study analyzed statistical data, assessed the potential for injuries in the event of a warning, and conducted a large-scale survey to gauge public attitudes on the issue.

An Aston University researcher has conducted the first experimental demonstration of intricate and previously theorised behaviours in the fundamental patterns that govern oscillatory systems in nature and technology.

Understanding and controlling how bacteria move through obstacle-filled environments has long been a challenge. A new model developed by a scientist at the Flatiron Institute can predict how bacteria will diffuse in crowded spaces, opening the door for strategies to control their spread.

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want an alternative to using an insulin pump or multiple daily injections (MDI) for insulin delivery.